January 6, 2026 – Athens, Greece: An official meeting was held in Athens on January 6 between the Ambassador of the Republic of Indonesia to Greece, H.E. Dr. Bebeb A.K. Nugraha Djundjunan, and the Founder and Director of RGCC International, Dr. Ioannis Papasotiriou.
During the meeting, both parties explored a range of opportunities for meaningful cooperation across the business, scientific, and academic sectors, with particular emphasis on advanced healthcare technologies.
The Ambassador underscored Indonesia’s strong interest in innovative healthcare solutions, particularly in the fields of cellular therapies and gene-based technologies. He noted that Indonesia is open to collaboration in leveraging RGCC’s expertise to strengthen the capacity of Indonesian hospitals and improve patient outcomes.
Within this context, the potential transfer of RGCC’s scientific expertise and know-how was discussed as a key factor in supporting Indonesia’s ongoing efforts to further strengthen and expand its healthcare system.
“The science and knowledge already exist,” stated Dr. Papasotiriou. “With the right regulatory frameworks and policy support in place, this knowledge can be effectively translated into tangible benefits for patients.”
Dr. Papasotiriou highlighted Indonesia’s proactive engagement in regulatory development and strategic partnerships as a positive example of how forward-looking policy approaches can facilitate broader access to advanced medical solutions. Such approaches may serve as a valuable reference for Greece and other regions seeking to enhance patient access to innovations in the medical field while maintaining high standards of safety, quality, and governance.
Further topics addressed during the meeting included medical tourism in the field of oncology, the development of private healthcare facilities serving international patients, preventive screening programs aimed at early diagnosis and risk reduction, access to innovative therapies, among others.
Such initiatives have the potential to improve patient outcomes, optimize disease management, and contribute to more sustainable healthcare systems by reducing the burden of late-stage disease. The meeting reaffirmed the shared view that collaboration, scientific innovation, and supportive regulatory environments are essential drivers for advancing modern healthcare.
This meeting builds upon RGCC’s interest in the Indonesian market and healthcare system. In 2025, RGCC entered into a letter of intent with Indonesian academic and healthcare partners, marking the initial stage of a collaborative framework aimed at strengthening institutional cooperation through joint research initiatives, cultural exchange, and academic mobility.
RGCC remains committed to engaging with governments, institutions, and stakeholders worldwide to support initiatives that enhance patient access to cutting-edge medical solutions and improve patient health outcomes.
About RGCC International:
RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine. Today, RGCC is a leading innovator in the field of oncology diagnostics. Using world-leading technology, equipment, and innovative techniques, our team of scientists has developed a range of liquid biopsies that help physicians track cancer progression and tailor treatment plans based on individual patient profiles.
For more info visit: rgcc-international.com